Cytek Biosciences, Inc. (CTKB)

Over the past six months, Cytek Biosciences' stock experienced several events. In Q3 2025, the company reported a loss but topped revenue estimates, with $52.3 million in revenue. Preliminary Q4 and full-year 2025 revenue results were announced, with expected total revenue for full-year 2025 to be approximately $201 million. An insider increased their holding by 169% in February 2026. The company presented at the 44th Annual J.P. Morgan Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference. The 52-week high for CTKB stock is $6.18, and the 52-week low is $2.37.

There is no explicit information available regarding specific seasonal fluctuations in demand for Cytek Biosciences' products and services. The company's revenue growth is influenced by factors such as service performance, unit volume growth, capital spending, shifting research priorities, and competition. Estimates of forecasted demand are based on expected product lifecycles, product development plans, and historical usage.

Cytek Biosciences develops and commercializes spectral flow cytometry instruments and associated reagents for high-parameter single-cell analysis. Their technology platform aims to provide enhanced sensitivity, resolution, and flexibility compared to traditional flow cytometry methods. Major products include Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters for cell analysis. The Aurora CS cell sorter leverages full spectrum profiling technology to broaden cell analysis applications. Additional cell analysis tools offered by the company are Amnis ImageStream imaging flow cytometers, Guava Muse cell analyzers, and Guava easyCyte flow cytometers. Orion reagent cocktail preparation systems are used for preparing reagents. The company also offers reagents and kits, including cFluor reagents, automated micro-sampling and sample loader systems, SpectroFlo software, and a cloud-based operating system.

Headquartered in Fremont, California, Cytek Biosciences has a global distribution network, serving academic institutions, biopharmaceutical companies, and clinical laboratories across North America, Europe, and Asia. A majority of its revenue is generated from the United States. The company also has offices and distribution channels across the globe and opened a new manufacturing facility in Singapore in early 2025 to anticipate continued global demand growth and diversify manufacturing capabilities.

In the past year, Cytek Biosciences was included on TIME's 2026 list of America's Growth Leaders. The Cytek® Muse® Micro Cell Analyzer won the BioTech Breakthrough Award for Drug Discovery Solution of the Year. Based on ratings from 7 Wall Street analysts in the last 12 months, the stock has a consensus "Hold" rating.

Cytek Biosciences is a publicly traded company with ownership distributed among various shareholders. Institutional investors collectively held 60.91% of the company's shares as of 2025. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Topline Capital Management, LLC, Hillhouse Capital Advisors, Ltd., Brown Capital Management Llc, State Street Corp, Millennium Management Llc, Dimensional Fund Advisors Lp, and Geode Capital Management, LLC. Individual insiders who own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, and William D Mccombe.